Atropine is a mydriatic agent, which clinically shows promising potential in treating progressive Myopia. Topical ophthalmic atropine sulfate has an extensive clinical history dating back several decades. Topical ophthalmic solution of 1% atropine sulfate has been approved worldwide for use in producing cycloplegia, mydriasis and in penalizing the healthy eye in treatment of amblyopia. CBT-009 is a novel ophthalmic formulation of atropine, which will substantially improve atropine stability in the formulation and ultimately product shelf life.